Power W J, Collum L M, Easty D L, Bloom P A, Laidlaw D A, Libert J, Sangers D, Wuokko M, Saksela T
Royal Victoria Eye and Ear Hospital, Dublin, Ireland.
Eur J Ophthalmol. 1993 Apr-Jun;3(2):77-82. doi: 10.1177/112067219300300205.
The results of this clinical study demonstrate that ciprofloxacin ophthalmic solution 0.3% is as safe and as effective as 0.5% chloramphenicol ophthalmic solution in the treatment of conjunctivitis and blepharitis of bacterial aetiology. Both agents achieved microbiological improvement rates in excess of 90% after 1 week's treatment. On ciprofloxacin 93.5% of patients were judged clinically cured or improved versus 84.6% on chloramphenicol after 1 week. There were no serious adverse affects. One patient in each group suffered drug-related side-effects (chemosis, erythema) which resolved on discontinuation or changing of therapy. Cirpofloxacin is not associated with the rare, but serious, side effect of aplastic anaemia which is associated with chloramphenicol use. On the evidence of this study ciprofloxacin would appear to be an appropriate agent for general use as a topical ophthalmic formulation.
这项临床研究结果表明,0.3%环丙沙星滴眼液在治疗细菌性结膜炎和睑缘炎方面与0.5%氯霉素滴眼液一样安全有效。两种药物在治疗1周后微生物学改善率均超过90%。使用环丙沙星治疗1周后,93.5%的患者临床判定治愈或好转,而使用氯霉素的这一比例为84.6%。未出现严重不良反应。每组各有1例患者出现与药物相关的副作用(球结膜水肿、红斑),停药或更换治疗后症状消失。环丙沙星不会引发氯霉素使用时罕见但严重的再生障碍性贫血副作用。基于本研究证据,环丙沙星似乎是一种适合普遍用作局部眼科制剂的药物。